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Background: Clinical cardiac cell therapy using autologous somatic stem cells is restricted by age and disease-
associated impairment of stem cell function. Juvenile cells possibly represent a more potent alternative, but the
impact of patient-related variables on such cell products is unknown. We therefore evaluated the behavior of
neonatal cord blood mesenchymal stem cells (CB-MSC) in the presence of serum from patients with advanced
heart failure (HF).
Methods: Human serum was obtained from patients with severe HF (n = 21) and from healthy volunteers (n = 12).
To confirm the systemic quality of HF in the sera, TNF-α and IL-6 were quantified. CB-MSC from healthy neonates
were cultivated for up to 14 days in medium supplemented with 10% protein-normalized human HF or control
serum or fetal calf serum (FCS).
Results: All HF sera contained increased cytokine concentrations (IL-6, TNF-α). When exposed to HF serum, CB-MSC
maintained basic MSC properties as confirmed by immunophenotyping and differentiation assays, but clonogenic
cells were reduced in number and gave rise to substantially smaller colonies in the CFU-F assay. Cell cycle analysis
pointed towards G1 arrest. CB-MSC metabolic activity and proliferation were significantly impaired for up to 3 days
as measured by MTS turnover, BrdU incorporation and DAPI + nuclei counting. On day 5, however, CB-MSC growth
kinetics approached control serum levels, though protein expression of cell cycle inhibitors (p21, p27), and
apoptosis marker Caspase 3 remained elevated. Signal transduction included the stress and cytokine-induced JNK
and ERK1/2 MAP kinase pathways.
Conclusions: Heart failure temporarily inhibits clonality and proliferation of “healthy” juvenile MSC in vitro. Further
studies should address the in vivo and clinical relevance of this finding.
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Cardiac cell therapy is currently being evaluated as a
treatment option for patients with severe heart failure
(HF) (reviewed in [1]). In contrast to experimental models
of heart disease, cell-based therapy in humans has brought
about only moderate improvements in heart function
and there is very little evidence of de novo formation of
cardiomyocytes. This mismatch between animal exper-
iments and human clinical trials may be explained by* Correspondence: stamm@dhzb.de
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reproduction in any medium, provided the orage and disease-related impairment of stem cell func-
tion in HF patients [2,3]. To circumvent the limited
regenerative capacity of autologous stem cells from
elderly and chronically sick patients, neonatal cell
products from healthy donors have been suggested as a
superior alternative. However, it has not yet been in-
vestigated whether these juvenile cells would withstand
the harsh environment upon transplantation into a failing
heart. Apart from ischemia and pathologic extracellular
matrix architecture, HF may affect stem cell function
through circulating disease-related humoral factors. An
abnormal molecular milieu is present in HF [4], and
several publications have pointed to a role for HF-
associated circulating factors in the modulation of adulttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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fied Angiostatin as an inhibitor of human bone-marrow-
derived mesenchymal stem cell (hBM-MSC) proliferation
and migration; and Gatta et al. showed that serum com-
position determines growth of colony-forming endothelial
progenitor cells (CFU-EC) [5,6]. The influence of humoral
factors on neonatal stem cell function, however, is still
unknown. We therefore sought to test the hypothesis that,
in vitro, HF serum factors impair the functionality of
neonatal cord blood mesenchymal stem cells (CB-MSC).
We chose neonatal CB-MSC from healthy donors because
this cell type is characterized by young chronological age
and absent disease-associated functional impairment, and
possesses a marked proliferation capacity and a broad
differentiation potential (reviewed in [7]). In summary, we
found that heart disease does have an impact on CB-MSC
biology as evident from impaired proliferation characteris-
tics, stimulation of apoptosis and activation of stress sig-
naling pathways.
Material and methods
Study population: heart failure patients and healthy
control subjects
The study was done in accordance with the Declaration
of Helsinki, with approval of the ethics committee of
Charité-University Medicine Berlin, and with informed
consent of all patients and volunteers. Blood samples
were collected from patients with chronic HF (n = 21)
during hospitalization. Patients were included in the study
if they had left ventricular ejection fraction (LVEF) <40%
as determined by echocardiography, with New York Heart
Association (NYHA) functional class III or IV, and an
indication for cardiac surgery including implantation of a
left ventricular assist device. Patients were excluded if they
were not clinically stable or had cancer, any active infec-
tion or an indication for heart transplantation. The clinical
details are summarized in Table 1. Blood samples were
also taken from 12 healthy control subjects. Detailed infor-
mation on those is also provided in Table 1.
Human serum preparation
Blood was drawn by venipuncture into S-Monovettes®
(Sarstedt, Nümbrecht, Germany) using the BD Vacutainer
Safety-Lok™ blood collection set (BD Medical, Heidelberg,
Germany). Serum off the clot was obtained from whole
blood which underwent the natural clotting process. Since
HF patients routinely receive anticoagulants, blood sam-
ples were subjected to a prolonged clotting period (3 h as
compared to 30 min: 20 min at room temperature (RT) to
initiate the clotting process followed by 2 h 40 min on ice
to prevent degradation of serum constituents). After cen-
trifugation for 15 min at 3500 g and 4°C, serum superna-
tants were sterile filtered. Aliquots were flash frozen and
stored in liquid nitrogen, because it took several weeks torecruit enough patients so that experiments with multiple
sera could begin. Hemolytic tubes were excluded.Protein normalization of human serum
The protein content of human blood varies with a number
of parameters at the time of blood sampling, such as liquid
intake, physical activities, drugs, disease status, and previ-
ous infusions [8]. To account for this, serum protein con-
centration was determined by Bradford assay (Carl Roth,
Karlsruhe, Germany) including interpolation from a stand-
ard curve established with bovine serum albumin (BSA),
and normalized to the lowest concentration (~37 mg/ml,
which corresponds to ~10% FCS supplementation) by
respective dilution in Gibco® D-PBS with Ca2+ and Mg2+
(PBS++) (Life Technologies, Darmstadt, Germany).Cytokine ELISA
To make sure that sera were indeed typical for patients
with chronic HF, selected cytokines were determined
using high sensitivity colorimetric assays: Human IL-6
Quantikine HS ELISA Kit (RnD Systems, Wiesbaden-
Nordenstadt, Germany) and Human TNF-α Quantikine
HS ELISA (RnD Systems). All immunoassays were
performed according to the manufacturer’s instructions.
Human serum samples were thawed and protein nor-
malized immediately before the assay.Standard cell culture of human CB-MSC
Cryopreserved human CB-MSC were provided by K.B.,
who isolated and expanded CB-MSC according to a previ-
ously published protocol [9]. Cord blood was obtained
with informed consent of the mother, according to the
principles outlined in the Declaration of Helsinki and with
approval of the local ethical committees in Mannheim and
Heidelberg (Ref. 48/05 reconfirmed in 2009). Passage (P)
2 cells were expanded in low glucose Gibco® DMEM
(DMEM-LG) (Life Technologies) supplemented with
10% FCS (Life Technologies, pre-tested batch 41F6495K)
and 1% penicillin/streptomycin (P/S) (Lonza, Basel,
Switzerland). Cells were seeded at a density of ~1000
cells/cm2 in T175 flasks; partial medium change was
given every 3 days. At subconfluency, cells were
subcultured using Gibco® TrypLE™ Express (Life Tech-
nologies), or cryopreserved in FCS supplemented with
10% DMSO (Carl Roth) and stored in liquid nitrogen.
Cells used for experiments originated from the umbilical
cord of a single healthy donor and had undergone 2–3
freeze-thaw cycles and ~20 population doublings, referred
to as P4 cells. Cell culture vessels employed throughout
the study were either CELLSTAR® (Greiner Bio-One,
Frickenhausen, Germany) or Nunclon™Δ Surface (Nunc,
New York, NY, USA) products.
Table 1 Characteristics of healthy controls and HF
patients
Healthy control
subjects (n = 12)
Heart failure
patients (n = 21)
Demographic data and medical
history
Age [years] 40 (3, 24–71) 60 (12, 31–82)
Sex (male/female) 6/6 (50%/50%) 15/6 (71%/29%)
Smoking status 4 (25%) 9 (43%)
HF duration [month] - 13 (4.6, 0.3-48)
Previous surgery - 0
Previous MI - 13 (62%)
Time since most recent
MI [month]
- 2.7 (1.8, 0.1-36)
Extent of CAD
One vessel - 0
Two vessels - 0
Three vessels - 21 (100%)
NYHA functional class
III - 13 (62%)
IV - 8 (38%)
Heart rate [bpm] - 92 (13)
Systolic blood
pressure [mmHg]
- 118 (26, 82–167)
Diastolic blood
pressure [mmHg]
- 76 (19, 54–104)
Etiology
Ischemic - 16 (76%)
Non-ischemic - 5 (24%)
Idiopathic - 0
Echocardiographic data
LVEDD [mm] - 153 (38, 93–232)
LVESD [mm] - 73 (26, 58–149)
LVEF [%] - 24.7 (13.4, 15–38)
Surgery
Ventricular assist device - 5 (24%)
Bypass graft - 12 (57%)
Valve - 5 (24%)
Non-cardiac disease
Allergy 1 (8%) 4 (19%)
S.p. apoplexia 1 (8%) 1 (5%)
Hypertension 3 (25%) 17 (81%)
Osteoporosis 1 (8%) 3 (14%)
Hypothyroidism 2 (17%) 0
Diabetes type II 1 (8%) 11 (52%)
Chronic obstructive
pulmonary disease
1 (8%) 3 (14%)
Table 1 Characteristics of healthy controls and HF
patients (Continued)
Pharmacological therapy
Aspirin 1 (8%) 12 (57%)
Heparin 0 15 (71%)
Coumadin 1 (8%) 3 (14%)
Statins 1 (8%) 14 (67%)
Loop diuretics 2 (17%) 15 (71%)
β-blockers 1 (8%) 5 (24%)
Digitoxin 0 8 (38%)
Metformin 1 (8%) 0
ACE Inhibitors 1 (8%) 17 (81%)
Amniodarone 0 6 (29%)
Amlodipine 1 (8%) 0
Biphosphonates 1 (8%) 0
Pantoprazole 0 18 (86%)
Catecholamines 0 6 (29%)
Data is expressed as number (percent) or as mean (SD, range).
ABBREVIATIONS: MI myocardial infarction, CAD coronary artery disease, NYHA
New York Heart Association, LVEDD left ventricular end-diastolic diameter,
LVESD left ventricular end-systolic diameter, LVEF left ventricular
ejection fraction.
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Several criteria (CB-MSC initial seeding density, human
serum concentration, exposure time, means and interval
of serum supplementation, necessity for dual supplemen-
tation using FCS and human serum) were examined for
the design of a suitable in vitro system. Unless otherwise
stated, final conditions were as follows: Cryopreserved
CB-MSC were thawed and plated at a density of 4000
cells/cm2 in medium supplemented with 10% FCS. After
cell attachment, on day 0, FCS was replaced by 10%
protein-normalized human serum. Complete medium
change was performed every 2 days. Total exposure time
was 5–14 days. Individual sera were not pooled, but tested
separately. Human serum from healthy donors served as
experimental control. In parallel, all experiments were also
performed with cells maintained under standard culture
conditions (FCS supplementation).
MTS metabolic activity assay and BrdU proliferation assay
The CellTiter 96® Aqueous Non-Radioactive Cell Prolif-
eration Assay (Promega, Mannheim, Germany) and the
colorimetric BrdU Cell Proliferation ELISA (Roche,
Mannheim, Germany) were performed according to the
manufacturer’s instructions on days 1, 3 and 5 on tripli-
cate wells of 96-well plates.
DAPI-based direct cell counting
Subsequent to MTS assay, cells were fixed in 4% parafor-
maldehyde (PFA) (Carl Roth) and stained with Molecular
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tent screener (PerkinElmer, Rodgau, Germany) was used
to capture 23 10X-images per well that covered the whole
culture surface. Harmony® software (PerkinElmer) was
used for image analysis, which was performed to quantify
CB-MSC numbers based on DAPI-stained CB-MSC nu-
clei. Since CB-MSC are single nucleated cells, nuclei
counts served as direct cell counts to validate indirect
proliferation readings acquired from colorimetric assays
(MTS, BrdU).
Phase contrast microscopy of cell morphology
Morphology of live unstained cells was examined by phase
contrast microscopy on days 1, 3, 4 and 5 of human serum
treatment.
Flow cytometric immunophenotyping
Cell harvests were washed in PBS and blocked in FACS
buffer (1% BSA, 0.05% sodium azide in PBS) for 15 min
at 4°C. Triple combinations of antibodies were employed
to stain 50,000 cells in 100 μl volume for 30 min at 4°C.
Propidium iodide (PI) (BD Biosciences, Heidelberg,
Germany) was added after 15 min to a final concentra-
tion of 5 μg/ml. Excess antibodies were washed off and
cells were resuspended in FACS buffer and analyzed in
a BD FACSCalibur flow cytometer (Becton Dickinson,
NJ, USA). Fifteen thousand events were acquired and
analyzed using FlowJo software (Tree Star, Ashland,
OR, USA). The following mouse antibodies were used:
Biozol (Eching, Germany): CD14-FITC, CD73-PE; Miltenyi
Biotec (Bergisch Gladbach, Germany): CD34-PE, CD45-
FITC; eBioscience (Frankfurt, Germany): CD90-APC;
antibodies-online (Aachen, Germany): CD105-FITC, HLA-
DR-FITC [10].
Tripotential mesodermal differentiation
For osteogenic and adipogenic differentiation, CB-MSC
were grown to subconfluency in the presence of 10%
human HF or control serum or FCS in 6-well plates (for
q-RT-PCR analysis) or 12-well plates (for stainings). After
7 days, osteogenic or adipogenic induction medium
(StemPro® Osteocyte/Adipocyte Differentiation Basal
Medium supplemented with StemPro® Osteogenesis/
Adipogenesis Supplement, Life Technologies) was
added and changed twice per week. After 21 days, cells
were fixed and stained with Alizarin Red S or Oil Red
O (Sigma-Aldrich, St. Louis, MO, USA) to confirm
osteogenic (calcium deposits) or adipogenic differenti-
ation (intracellular lipid granules). For chrondrogenic
differentiation a 3-D culture system was used: After 7
days of treatment with 10% human HF or control serum
or FCS, CB-MSC were subcultured. Approx. 3.5×105 cells
were pelleted in 15 ml tubes (for q-RT-PCR analysis),
droplets containing 0.8×105 cells were seeded into 12-wellplates to generate micromass cultures (for stainings). In-
duction medium (StemPro® Chondrocyte Differentiation
Basal Medium supplemented with StemPro® Chondro-
genesis Supplement, Life Technologies) was added and
changed twice per week. After 21 days, micromass cul-
tures were fixed and stained with Alcian Blue (Carl Roth)
to visualize proteoglycan deposits. Undifferentiated cells
served as negative controls.
Quantitative real-time PCR
Total RNA was extracted from undifferentiated (after 7
days of human serum treatment) and differentiated cells
(after 7 days of human serum treatment and 21 days of
differentiation) using the Qiagen RNeasy Mini Kit
(Qiagen GmbH, Hilden, Germany). Contaminating gen-
omic DNA was removed with DNAse I (Sigma-Aldrich).
Subsequently, 100 ng of each RNA sample were random
hexamer primed and reverse transcribed into cDNA
using the Invitrogen™ SuperScript® III First-Strand Syn-
thesis System (Life Technologies). Real-Time PCR was
performed using the Applied Biosystems® Power SYBR®
Green PCR Master Mix (Life Technologies) and the
Eppendorf Mastercycler ep gradient S realplex2 (Eppendorf
AG, Hamburg, Germany) by combining 12.5 μl SYBR
Green master mix, 2 μl primer mix (forward:reverse
1:1, final concentration 800nM), 5.5 μl sterile ddH2O
and 5 μl cDNA (1.25 ng template per reaction) per well
in an Applied Biosystems® MicroAmp® Optical 96-Well
Reaction Plate (Life Technologies). Each PCR reaction
was performed in triplicates. The following PCR pro-
gram was applied: initial denaturation: 95°C 10 min; 45
cycles: 95°C 15 s, 60°C 30 s, 72°C 30 s; final step: melt-
ing curve program. PCR primers were designed using
Primer3 software [11]: (5′-3′): Tissue non-specific al-
kaline phosphatase, ALP (F: GGAAATCTGTGGGCAT
TGTG, R: CCCTGATGTTATGCATGAGC); Peroxisome
proliferator-activated receptor gamma, PPARγ (F: TGCA
GTGGGGATGTCTCATA, R: CAGCGGGAAGGACTTT
ATGT); Trancription factor SOX-9, SOX9 (F: GAGGA
AGTCGGTGAAGAACG, R: AAGTCGATAGGGGGCT
GTCT); Ribosomal protein L13, RPL13 (F: CCTGGAG
GAGAAGAGGAAAGAGA, R: TTGAGGACCTCTGTG
TATTTGTCAA). PCR primers were purchased from Life
Technologies. Relative gene expression levels of lineage-
specific markers in differentiated and undifferentiated cells
were quantified by the following alogorithm: E-Δct. RPL13
served as reference gene.
Flow cytometric cell cycle analysis
Cell harvests were resuspended in PBS++ at a concentra-
tion of 106 cells/ml and fixed in ice cold (−20°C) 70%
ethanol for at least 2 h at 4°C. Next, cells were washed
in PBS++ and stained with PI solution (0.1% TritonX100,
10 μg/mL PI (Sigma-Aldrich), 100 μg/mL RNase A (Carl
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DNA content was assessed through PI fluorescence, which
was determined in a BD FACSCalibur flow cytometer.
Fifteen thousand events were acquired in a pre-set “single
cell” gate that excluded cell aggregates, and were analyzed
using FlowJo software.
CFU-F clonal assay
CB-MSC were subcultured, suspended in DMEM
supplemented with 20% FCS (to ensure efficient attach-
ment) and seeded at a density of 2 cells/cm2 into 6-well
plates. Subsequent to visual inspection of seeding suc-
cess, FCS was replaced by 10% human HF or control
serum. After 14 days of treatment, cells were washed
with PBS++, fixed with cold (4°C) 4% PFA for 30 min at
RT, and were stained with 0.5% crystal violet solution
(Carl Roth) for 30 min at RT on a rocking shaker. After-
wards excess stain was washed off and plates were air
dried. Quantitative (number) and qualitative (size) CFU-F
data was obtained from triplicate wells. All events
seen in the plates (single cells, clusters comprised of
2, 4, 8, >10, >20, >50, >100, >200 or >500 cells) were
counted.
AnnexinV flow cytometric apoptosis detection
Cell harvests and supernatants were used to determine
apoptosis by AnnexinV FITC Apoptosis Detection Kit
I (BD Biosciences) according to the manufacturer’s
instructions. Necrotic cells were discriminated by PI
counterstaining. Fifteen thousand events were acquired
in a BD FACSCalibur flow cytometer and analyzed
using FlowJo software.
Western blot
After 5 days of human serum treatment total protein
from CB-MSC was isolated and quantified using Pro-
Prep Protein Extraction solution (Intron Biotechnology,
South Korea) and DC Protein Assay (Bio-Rad, Hercules,
CA, USA) or BCA Protein Assay Kit (Pierce/Thermo
Scientific, Rockford, IL, USA). Protein (15–20 μg) was
separated by discontinuous SDS-PAGE and blotted to
0.45 μm nitrocellulose membranes (Bio-Rad, Carl Roth)
by o/n wet tank or 40 min semidry transfer. Membranes
were blocked for 1.5 h at RT in 5% skim milk prepared
in TBS-T (10 mM TrisHcl pH 7.4, 100 mM NaCl, 0.1%
Tween20 in ddH2O), washed with TBS-T and incubated
with primary antibody o/n at 4°C, washed with TBS-T
again and were stained with HRP- or IRDye-labeled sec-
ondary antibodies for 1 h at RT. Chemiluminescent pro-
tein detection was performed using the Amersham™ ECL
Western Blotting Detection Reagents (GE HEALTHCARE,
Little Chalfont, UK) and the FluorChem® HD2 Imaging
System (Alpha Innotech, Santa Clara, CA, USA). Infrared
protein detection was performed using the OdysseyInfrared Imaging System (LI-COR Biosciences, Lincoln,
NE, USA). Primary mouse or rabbit antibodies were:
Upstate/Millipore (Billerica, MA, USA): Bax; Abcam
(Cambridge, UK): alpha Tubulin, p21, p16, p38, Caspase 3;
Millipore: GAPDH, pp38; Cell Signaling (Danvers, MA,
USA): CDK1, Cyclin E2, Cyclin D1, Cyclin B1, p27, JNK,
pJNK, ERK1/2, pERK1/2, GAPDH; Santa Cruz Biotech-
nology (Santa Cruz, USA): CDK4, CDK2, pp53. Secondary
goat antibodies were: anti-rabbit or anti-mouse IgG-HRP
(Zymed/Life Technologies) and IRDye®680LT anti-mouse
IgG or IRDye®800CW anti-rabbit IgG (LI-COR Bio-
sciences). Band quantification was performed by ImageJ
(NIH, Bethesda, MD, USA) as described elsewhere [12]
(FCS treated cells served as standard).
Statistics
Unless otherwise stated, medians (IQR) given were
obtained from results of experiments performed with
group sizes of at least four separate control or HF sera.
Normal distribution provided, ANOVA with Bonferroni’s
post-hoc test was done, otherwise the Kruskal-Wallis-
Test or Mann–Whitney U-Test were applied to test for
differences between groups. A general linear model was
constructed to test the impact of several clinical vari-
ables on CB-MSC behavior within the HF patient cohort
(see below). Statistical analyses were performed in SPSS
20 (IBM Corporation, Somers, NY, USA).
Results
HF serum cytokines
Concentrations of IL-6 and TNF-α, common HF bio-
markers, were determined by high sensitivity ELISA
(Figure 1). Compared to human control serum, IL-6 and
TNF-α concentrations were significantly higher in all
HF sera (IL-6: control, 0.42 pg/ml (0.37-0.47 pg/ml) vs.
HF, 6.83 pg/ml (4.26-14.04 pg/ml), p = 0.002; TNF-α:
control, 0.68 pg/ml (0.63-0.74 pg/ml) vs. HF, 1.41 pg/ml
(1.28-1.97 pg/ml), p = 0.002). However, we were not able
to demonstrate a significant correlation between cyto-
kine content and CB-MSC proliferation or apoptosis in
individual sera (see below).
HF serum treatment does not affect basic MSC
characteristics
After 5 days of HF serum treatment, CB-MSC had
retained their spindle-shaped morphology and plastic
adherence (Figure 2A, E, I). Flow cytometric analysis of
CB-MSC surface marker expression revealed neither
qualitative nor significant quantitative differences between
the three groups after 5 days of treatment (Figure 2P-V).
In all cell populations analyzed, at least 98% of live cells
expressed CD73, CD90 and CD105; less than 2% of live
cells expressed CD14, CD34, CD45 and HLA-DR. Differ-
entiation of CB-MSC towards the osteogenic, adipogenic
AB
Figure 1 HF serum biomarkers. Serum cytokines in HF patients
measured by high sensitivity ELISA. Compared to human control
serum, both IL-6 (A) and TNF-α levels (B) were significantly higher in
all HF sera. The boxplots indicate interquartile range (box), median
(line), range (whiskers) and outliers (+/−).
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all cultures (human HF, control serum and FCS), as shown
by the respective stainings (Figure 2B-D, F-H, J-L). Gene
expression analysis of lineage-specific markers confirmed
that differentiation induced the upregulation of ALP
(osteogenesis), PPARγ (adipogenesis) and SOX9 (chondro-
genesis) in all groups (relative gene expression in differen-
tiated vs. undifferentiated cells, p = 0.03 for all groups and
all markers). Interestingly, ALP expression in HF serum
treated undifferentiated cells was elevated compared to
undifferentiated cells treated with human control serum
or FCS, and did not increase further during osteogenic dif-
ferentiation (Figure 2M-O). Quantitatively, the osteogenic
and chondrogenic differentiation potential did not differ
between the human HF, control serum and the FCS group,
as there was no relevant difference of lineage-specificmarker expression in differentiated cells of all groups
(ALP, p = 0.6; SOX9, p = 0.1). Solely, PPARγ expression in
adipogenic differentiated HF serum treated cells was
markedly lower compared to the FCS control (p = 0.02).HF alters clonogenicity and colony formation pattern of
CB-MSC
CB-MSC clonogenicity was examined by colony forming
unit-fibroblast (CFU-F) assay. The quantification of
clonal efficiency (number of colonies comprising more
than 50 cells per number of initially plated cells) showed
a significantly lower percentage of clonogenic cells in
the HF group (human control, 53.0% (42.6-56.2%) vs. HF,
35.7% (33.3-42.0%), p = 0.005; FCS, 47.8% (45.7-49.7%) vs.
HF, p = 0.05; Figure 3A). Moreover, the quantitative ana-
lysis of colony size revealed a difference in the pattern of
cluster size between the treatment groups. Notably, in the
presence of HF serum CB-MSC formed more small-sized
clusters (composed of <50 cells) but fewer large-sized clus-
ters (composed of >200 cells) than in human control
serum or FCS (Figure 3B-D).Impaired proliferation of CB-MSC upon HF serum
treatment
Here, we sought to elucidate the kinetics of cellular
proliferation and metabolic activity in greater detail. Ir-
respective of the type of serum, CB-MSC grew steadily,
as evident from the readouts of three independent pro-
liferation assays (Figure 4), but we observed marked
differences in growth rate between the groups. Overall,
CB-MSC proliferation was significantly suppressed in
the HF group during the first 3 days of treatment and
accelerated during the final phase of observation. In
human control serum and FCS, growth rate was high
in the beginning and consequently reached saturation
earlier. In the BrdU cell proliferation assay, CB-MSC
DNA synthesis levels were significantly lower after 1
and 3 days of exposure to HF serum as compared to
human control serum (Figure 4A). After 5 days, how-
ever, the proliferation status of HF serum treated
CB-MSC approached that of control serum treated
CB-MSC at 5 days. The DAPI-based direct cell counting
method confirmed this observation (Figure 4B). To
further assess the metabolic activity of CB-MSC, a
MTS assay was performed. Corresponding to prolifera-
tion behaviour seen with BrdU and DAPI counting,
metabolic activity was significantly reduced within the
first 3 days of treatment. By day 5, however, HF serum
treated CB-MSC reached metabolic activity levels that
were significantly higher than those reached with
human control serum, and comparable to those with
FCS (Figure 4C).
Figure 2 (See legend on next page.)
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Figure 2 Basic MSC properties in response to HF serum treatment. A, E, I: Phase contrast imaging of CB-MSC morphology did not reveal
obvious differences between FCS, the human control and the HF serum group. Scale bar = 100 μm. B-D, F-H, J-L: Tripotential mesodermal differentiation
capacity: Osteogenesis (calcium deposits) was visualized by Alizarin Red S (B, F, J) (bar = 250 μm), adipogenesis (lipid vesicles) by Oil Red O (C, G, K)
(bar = 50 μm) and chondrogenesis (proteoglycans) by Alcian Blue staining (D, H, L) (bar = 125 μm).M-O: Relative gene expression of lineage-specific
markers in undifferentiated and differentiated cells: osteogenesis, ALP (M), adipogenesis, PPARγ (N), chondrogenesis, SOX9 (O). The boxplots indicate
interquartile range (box), median (line), range (whiskers) and outliers (+/−). * p < 0.05 vs. undifferentiated cells. GOI: gene of interest. P-V: Surface marker
expression pattern of CB-MSC, as examined by flow cytometry, was not affected by HF serum treatment. Shown are histograms for CD73 (P), CD90 (Q),
CD105 (R), CD14 (S), CD34 (T), CD45 (U) and HLA-DR (V), in which cell counts are plotted against fluorescence intensity. All histograms are representative
for both human serum groups and the FCS control.
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presence of HF serum
After 5 days of cultivation of CB-MSC in human serum,
we determined the distribution of single cells within the
three cell cycle phases (G0/G1, S, G2/M) by flow
cytometric quantification of DNA content in cells
stained with PI (Figure 5A). As expected, the majority
(>70%) of cells were in the G0/G1 phase and the
remaining cells were almost equally distributed betweenFigure 3 Clonogenicity and colony pattern of CB-MSC in response to
in percent (number of colonies comprising more than 50 cells per number of
significantly reduced in the HF group. The boxplot indicates interquartile rang
frequencies of cell cluster size categories in percent for single samples of all g
(<50 cells) and a decrease in the number of large (>200, >500 cells) clusters. B
cluster (B, C). Scale bars = 1 mm.the S and G2/M phases. However, we found a difference
between human HF and control serum or FCS regarding
the percentage of cells in the G0/G1 and S phase. In the
HF group there were significantly more cells in G0/G1
(human control, 76.9% (74.7-84.1%) vs. HF 88.6% (83.9-
89.6%), p = 0.04; FCS, 78.1% (76.8-81.7%) vs. HF, p < 0.05)
and fewer cells in the S phase (human control, 8.2%
(6.5-8.8%) vs. HF, 4.6% (4.3-5.7%), p = 0.04; FCS, 8.6%
(7.1-9.9%) vs. HF, p = 0.006). Interestingly, the percentage ofHF. Clonal capacity was determined by CFU-F assay. A: Clonal efficiency
plated cells) for each experimental group. CB-MSC clonal efficiency was
e (box), median (line), range (whiskers) and outliers (+/−). B-D: Relative
roups (D). In the HF group there was an increase in the number of small
ar = 50%. Representative bright field images of a typical large and a small
AB
C
Figure 4 CB-MSC proliferation in response to HF serum. To assess
CB-MSC kinetics of proliferation and activity in response to individual
sera, three independent assays were performed with P4 cells after 1, 3
and 5 days of treatment. A: DNA synthesis levels were obtained from
BrdU assay. Graphs show optical densities recorded at 450 nm (OD 450
nm) for all treatment groups. B: DAPI-based cell counting approach for
direct quantification of CB-MSC number. C: Metabolic activity
determined by MTS assay, given as optical density at 490 nm. In all
assays, CB-MSC proliferation was impaired after 1 and 3 days, but not
after 5 days of treatment with HF serum as compared with human
control serum treatment. The effect of time and group and their
interaction were determined by ANOVA for repeated measurements.
The boxplots indicate interquartile range (box), median (line), range
(whiskers) and outliers (+/−).
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FCS group (human control, 10.0% (5.2-11.5%) vs. HF, 6.4%
(5.6-9.2%), p = 1; FCS 12.8% (10.1-14.1%) vs. HF, p = 0.01).
Insights into the molecular cell cycle machinery of HF
serum treated CB-MSC
By immunoblotting, we monitored the expression of stage
specific proteins that drive cell cycle progression and actin its regulation. We studied the expression of cyclin
dependent kinases (CDK), their activating cyclins and their
inhibitors (CDKI) contributing to G1 phase progression
(CDK4, Cyclin D1, CDKI p16INK4A), G1-S phase transition
(CDK2, Cyclin E2, CDKI p21CIP1 and p27KIP1) and M
phase entry (CDK1, Cyclin B1, CDKI p21CIP1). The data
are summarized in Figure 5B. While Cyclin D1 expression
was elevated and p16 unchanged in response to HF serum
(adjusted band densities: Cyclin D1: human control, 0.83
(0.71-1.2) vs. HF, 2.49 (1.81-3.17), p < 0.05; p16: human
control, 0.55 (0.43-0.72) vs. HF, 0.39 (0.32-0.5), p = 0.2),
completion of G1-S phase transition as well as the G2 and
M phase of the cell cycle were clearly inhibited as
evidenced by upregulation of p21 and p27, and a trend to-
ward downregulation of Cyclin B1 (p21: human control,
1.23 (0.91-1.4) vs. HF, 2.35 (2.06-2.44), p = 0.03; p27:
human control, 1.12 (0.94-2.09) vs. HF, 6.86 (5.59-
8.77), p = 0.03; Cyclin B1: human control, 2.32 (1.70-
2.79) vs. HF, 1.65 (1.31-1.78), p = 0.2). This pattern
indicates that, in response to HF serum, most CB-MSC
rest in the G1 phase of the cell cycle, and are not able
to progress despite a certain pro-mitotic stimulation
(Cyclin D1 upregulation).HF serum treatment triggers apoptosis in CB-MSC
We also sought to investigate the role of apoptotic events
in HF serum treated CB-MSC cultures and studied plasma
membrane alterations and the expression of proteins in-
volved in the initiation and execution of CB-MSC death
(Figure 6). Flow cytometric analysis of AnnexinV stained
cells (AnnexinV + and PI-) revealed a significantly higher
number of cells that had translocated phosphatidyl serine
to the outer surface of their plasma membranes in the
HF group (human control, 2.03% (1.77-2.48%) vs. HF,
3.13% (2.35-4.18%), p = 0.03; FCS, 2.26% (2.16-2.64%)
vs. HF, p = 0.6). By PI staining, the proportion of nec-
rotic cells (PI+) was not significantly different between
human control, HF serum and FCS treated cells, nei-
ther was the percentage of viable (AnnexinV- and PI-)
cells (necrotic cells: overall p = 0.07; viable cells: overall
p = 0.1). Western blot analysis of pro-apoptotic pro-
teins showed markedly increased protein levels of
cleaved Caspase 3 in the HF treatment group after 5
days of exposure (adjusted band densities: human con-
trol, 1.74 (1.58-2.28) vs. HF, 7.16 (3.48-7.69), p = 0.03).
While the intergroup difference in phosphorylated p53
expression indicated a trend towards increased levels
(p = 0.07), but lacked definitive statistical significance,
Bax protein expression did not differ between the
groups (adjusted band densities: phospho-p53: human
control, 0.56 (0.32-0.8) vs. HF, 1.9 (0.68-2.35), p = 0.07;
Bax: human control, 0.56 (0.51-0.72) vs. HF, 0.61 (0.58-
0.63), p = 0.5).
AB
Figure 5 Cell cycle state of CB-MSC upon HF and control serum treatment. A: Cell cycle status of individual cells was determined after 5 days
of HF serum treatment by flow cytometric analysis of DNA content of cells stained with PI. The graphs depict the percentage of cells present in each
cell cycle phase. Compared to the human control serum and the FCS group, the number of actively cycling cells in the HF group was significantly
lower. B: After 5 days of treatment with either human control, HF serum or FCS, protein expression levels of cyclin dependent kinases (CDK), their
positive (cyclins) and negative regulators (CDK inhibitors/CDKI of the INK4A and CIP/KIP family) involved in G1 progression (column 1), G1-S transition
(column 2) and M phase entry (column 3) were determined by Western blot. Boxplots display adjusted band densities normalized to FCS for both
human treatment groups. HF serum treatment blocks cell cycle progression of CB-MSC through upregulation of p21 and p27. The boxplots indicate
interquartile range (box), median (line), range (whiskers) and outliers (+/−).
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stimulus into CB-MSC response
Serum from HF patients contains a variety of factors
that may bind to plasma membrane receptors and initi-
ated intracellular signaling cascades leading to a prolif-
eration block and apoptosis. Typically, such stress
signals are relayed by mitogen activated protein (MAP)
kinases, which activate a variety of transcription factors.
We therefore studied the expression and phosphoryl-
ation of the three downstream effector MAP kinases,
ERK1/2, JNK and p38. As seen in Figure 7, p38 proteinexpression remained unchanged in response to HF
serum, but JNK total protein expression (adjusted band
densities: human control, 1.65 (1.49-1.69) vs. HF, 5.80
(4.75-6.01), p = 0.02) and phosphorylated JNK (human
control, 1.81 (1.25-2.47) vs. HF, 7.01 (3.26-7.68), p = 0.03)
were significantly elevated, while the phosphorylated-to-
total ratio of ERK1/2 was reduced (human control, 0.6
(0.46-0.69) vs. HF, 0.36 (0.29-0.39), p < 0.05). Usually JNK
is activated by phosphorylation only, resulting in a higher
ratio of phosphorylated-to-total JNK, while here there was
clearly also transcriptional upregulation of JNK expression,
A B C
E FD
Figure 6 HF serum provokes apoptosis in CB-MSC. A-C: Plasma membrane alterations (translocation of phosphatidyl serine) were assessed by flow
cytometric analysis of cells subjected to a combined staining with AnnexinV (AV) and Propidium Iodide (PI). Boxplots show the percentages of dead
(PI+) (A), apoptotic (AV+, PI-) (B) and viable cells (AV-, PI-) (C). There were significantly more apoptotic cells in the HF group. D-F: Western blots were
performed to determine intracellular amounts of pro-apoptotic proteins, such as phospho-p53 (D), Bax (E) and active Caspase 3 (F). Boxplots illustrate
quantified and adjusted band densities normalized to FCS for the human serum groups. Compared to the human control serum group, the HF group
exhibited markedly higher levels of Caspase 3, whereas Bax expression did not differ. The boxplots indicate interquartile range (box), median (line),
range (whiskers) and outliers (+/−).
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and the extended period of time the cells were subjected
to it.
Heart failure subgroup analysis
We also studied the impact of clinical variables within
the HF patient cohort on the clonogenicity and prolifer-
ative capacity of CB-MSC. Specifically, patient age, gen-
der, ischemic vs. non-ischemic heart disease, LVEF, IL-6
and TNF-α serum levels and the need for mechanical
circulatory support were tested as continuous or cat-
egorical variables, respectively. In the multivariate ana-
lysis, none of the clinical variables had significant impact
on CB-MSC behavior. However, when the data were
stratified according to the presence of previous myocar-
dial infarction, we found that, compared with serum
from healthy control subjects, clonal efficiency was only
reduced in serum from patients with previous myocardial
infarction (MI) (Figure 8).
Discussion
Since the regenerative capacity of HF-patient derived
stem cells is limited through age and disease [13,14], the
use of neonatal cell products for cardiac cell therapy
may represent a better alternative. It is, however, un-
known whether the performance of these juvenile cells
would be affected by the various stresses imposed by
the diseased organism. We therefore investigated thebehavior of CB-MSC in response to serum from patients
with severe HF. CB-MSC maintained their principal MSC
characteristics including surface marker phenotype, osteo-
genic, chondrogenic and limited adipogenic differentiation
capacity. This robustness of the minimal MSC criteria has
also been shown for adult hBM-MSC in autologous and
allogeneic human serum from healthy individuals [15], as
well as in the presence of autologous human serum from
patients with heart disease [16]. Only under more forceful
manipulation of MSC in vitro, such as exposure of MSC
to local anesthetics or replicative senescence in high pas-
sages do MSC display detectable changes in morphology
and differentiation capacity [17,18]. While the minimal
MSC properties withstand most external factors, clonality
and proliferative capacity are more susceptible. In our
experiments, clonal efficiency was reduced in the pres-
ence of HF serum, and the colonies that did develop
were predominantly small. Thus, within a CB-MSC
population some cells are inhibited to divide at all,
whereas others are significantly slowed down in doing
so. Similar phenomena have been described for cells of
endothelial and hematopoietic lineage, where thera-
peutic interventions in patients partially reversed the
inhibitory serum effects [6,19]. Interestingly, the colony-
forming ability of endogenous hBM-MSC seems to be
activated in patients with cardiovascular risk factors, but
the majority of the patients in that study had coronary
artery disease but not HF [16].
AB
C
Figure 7 Signal transduction in CB-MSC in response to HF and control serum. Immunoblot analyses were performed for p38 (A), JNK (B) and
ERK1/2 (C) after 5 days of CB-MSC culture in medium supplemented with either human control, HF serum or FCS. Boxplots show expression levels of
total or phosphorylated proteins as adjusted band densities normalized to FCS and the calculated phosphorylation status plotted as ratio of
phosphorylated-to-total protein for both human serum groups. In response to HF serum, JNK seemed to be transcriptionally upregulated, whereas
ERK1/2 phosphorylation was clearly reduced. The boxplots indicate interquartile range (box), median (line), range (whiskers) and outliers (+/−).
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CB-MSC proliferation as measured by BrdU incorpor-
ation, direct cell counting and MTS test was initially
inhibited by HF serum. This was associated with strong
upregulation of cell cycle inhibitors p21 and p27 that
block progression to the S, G2 and M phase. Accord-
ingly, the majority of CB-MSC rested in the G1 phase.
Our finding of concomitant Cyclin D1 upregulation in-
dicates attempted or beginning mitosis and may reflect
the reversal of the proliferation block at day 5. Overall,
the HF induced CB-MSC depression is in line with ob-
servations made by Yamahara et al. [5], who used adult
hBM-MSC and identified Angiostatin as one mediator
of HF induced MSC depression. In our experiments,
however, MSC proliferation kinetics caught up with and
metabolic activity even exceeded those observed in hu-
man control serum around day 5. The most straightfor-
ward explanation for this phenomenon is that MSC
adapt to the presence of HF serum factors and compen-
sate for the initial proliferation inhibition. Possible
mechanisms include downregulation of surface recep-
tors involved, as in agonist-induced desensitization of,
for instance, adrenergic receptors. In addition to attenu-
ation of inhibitory signaling, activation of stimulatoryintracellular mechanisms may also play a role. It may be
argued that methodological factors such as degradation
of serum factors in the culture medium also played a role,
but the medium was completely replaced every 48 hours.
HF serum treatment also triggered MSC apoptosis, as
evidenced by increased phosphatidyl serine exposure and
Caspase 3 activation. Such a pro-apoptotic effect of HF
serum has also been noted by Mammi et al., who used
endothelial cells from healthy donors as a model [20].
Expression of Bax (Bcl-2-associated X protein), which is
involved in mitochondrial membrane permeabilization,
was not upregulated in our model. One explanation for
this contradictory finding is that upon activation Bax
changes its conformation, translocated to the outer mito-
chondrial membrane, and induced cytochrome C release,
so that transcriptional activation is not required to induce
or accelerate apoptotic cell death (reviewed in [21]).
Regarding the intracellular signaling pathways, it is well
established that MAP kinases relay stress signals upon
extracellular stimulation with, for instance, growth factors
and cytokines, and among the targets of MAP kinases are
regulators of proliferation and apoptosis [22]. The down-
stream effector MAP kinases are ERK1/2, JNK and p38, all
of which directly activate nuclear transcription factors. We
Figure 8 Impact of clinical variables on CB-MSC behavior.
Clonal efficiency stratified according to the presence of myocardial
infarction (MI) in the patient’s history. Here, only serum from patients
with previous MI has signficantly reduced clonality. Please note the
limitations of this subgroup analysis that are discussed in the text.
The boxplot indicates interquartile range (box), median (line), range
(whiskers) and outliers (+/−).
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ylation, possibly due to lower levels of growth factors in
HF sera, which may account for impaired proliferation in
CB-MSC. We also found that total expression of JNK as
well as the amount of phosphorylated JNK were signifi-
cantly elevated, so that the ratio of phosphorylated to total
JNK remained constant despite clear activation of the
pathway. This transcriptional regulation of JNK is unusual
and underscores the profound effect of HF serum on CB-
MSC. Activation of p38, however, does not seem to play a
major role. This finding may surprise because p38 is typic-
ally strongly induced by inflammatory cytokines, while
JNK mediates cellular response to environmental stresses
(oxidative stress and DNA damage for instance). MAP
kinase pathways leading to JNK are typically activated by
FAS death receptors, but also by inflammatory cytokine
receptors including TNF-α and TGF-β. A more detailed
analysis of HF induced signaling events in somatic stem
cells may be necessary in the future.
It was beyond the scope of this study to identify the
components of HF serum that are responsible for the tem-
porary MSC depression. As mentioned above, Yamahara
et al. described a prominent role of Angiostatin in the
inhibition of hBM-MSC by serum from patients with
HF [5]. However, it may be safe to assume the effect of
HF serum on CB-MSC biology is the result of concerted
cytokine actions within a tremendous protein pool. Inaddition, drugs used for palliative treatment of HF, neu-
rohormones and reactive oxygen species may also play a
role [4].
Limitations of the study
The in vitro setting we chose for our experiments is clearly
a very artificial environment that is far from mimicking
the situation in vivo, especially in man. Further studies in
long-term in vitro settings as well as in vivo are needed to
solidify the evidence. Working with pooled patient sera
may have provided more robust data in some experiments,
but we chose to test the sera separately in order to be
able to test for patient-specific confounding factors.
Several groups that have pioneered the isolation and
characterization of CB-MSC used higher FCS concen-
trations in their protocols, so that one may suspect that
our cells were suffering from low serum concentrations
throughout [23]. We chose to conduct our experiments
with 10% serum because, first, the primary CB-MSC
cultivation and expansion (K.B.) was done this way, and,
second, we had only a limited volume of patient serum
available for our experiments. It is not possible, either,
to infer from our data what the most important molecu-
lar stimuli of the depressive HF effects are. In addition
to having heart failure, our patients received a multitude
of different pharmaceuticals, of which each may inter-
fere with CB-MSC function. Again, further studies
would be needed to dissect these effects. In the univari-
ate analysis we found that serum from patients with
previous myocardial infarction may inhibit CB-MSC
more than that of HF patients without MI (Figure 8).
However, these data must be interpreted with caution,
because cohort size is very small after stratification.
Finally, we worked with a multitude of sera but all our
CB-MSC were from the same batch. We chose this
approach to limit possible confounding factors with
CB-MSC and feel that this is justified because neonatal
cells are very uniform and have not been subjected to
age, disease and lifestyle-related changes. However, con-
firmation of our data in other CB-MSC batches would
clearly be necessary if immediately relevant conclusions
were to be drawn.
Conclusion
We found that serum from patients with advanced HF
temporarily inhibits the proliferative performance of
“healthy” neonatal cord blood-derived MSC. This prolif-
eration block seems to be overcome after 5 days in our
experimental setting, but reduced number of colony-
forming units and upregulation of several molecular cell
cycle inhibitors remain detectable beyond that point.
These data confirm the inhibitory impact of HF on stem
cell populations, and demonstrate that even allogeneic
neonatal cells are affected by this phenomenon. Although
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setting, this kind of study gives valuable insight into the
behavior of exogenous therapeutic cell products in re-
sponse to the diseased recipient organism. Ultimately,
such studies may lead to the development of personalized,
patient-specific cell therapies that are adapted to the indi-
vidual patient’s response.
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